Ludmila Yu. Milovanova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ludmila Yu. Milovanova has a total of 116 co-authors. Here are the top co-authors by number of shared publications:
- Svetlana Yu. Milovanova
Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation
17 shared publications - Marina V. Taranova
Sechenov First Moscow State Medical University (Sechenov University)
14 shared publications - Alexey V. Volkov
Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation
10 shared publications - Sergey V. Moiseev
Sechenov First Moscow State Medical University (Sechenov University); Lomonosov Moscow State University
8 shared publications - Vasilii Vladimirovich Kozlov
Azerbaijan Sport Academy, Baku
8 shared publications - Kirill S. Nezhdanov
Lomonosov Moscow State University
7 shared publications
Latest Publications
- Open Access
- 20 December 2025
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 97 (11) , 955-959
Cryoglobulinemia and HCV-infection: stages of study
The article presents the main stages of studying cryoglobulinemia and the associated clinical symptom complex as a manifestation of cryoglobulinemic vasculitis. Achievements in the study of hepatitis C virus are shown: the etiological role of the hepatitis C virus, pathogenesis, diagnosis. Variants of the course are considered, modern criteria for differential diagnosis, prognosis, choice of tactics and treatment methods are given.
- 20 December 2025
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 97 (11) , 955-959
Open AccessCryoglobulinemia and HCV-infection: stages of study
The article presents the main stages of studying cryoglobulinemia and the associated clinical symptom complex as a manifestation of cryoglobulinemic vasculitis. Achievements in the study of hepatitis C virus are shown: the etiological role of the hepatitis C virus, pathogenesis, diagnosis. Variants of the course are considered, modern criteria for differential diagnosis, prognosis, choice of tactics and treatment methods are given.
- Open Access
- 12 July 2025
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 97 (6) , 528-533
Gut microbiota: Historical essay and role in nephrology
The article covers the main stages of intestinal microbiota (MB) research from ancient to modern times and addresses the features of the interaction between intestinal MB and renal diseases, the gut-kidney axis. It is believed that for the first time, MB was mentioned in one of the treatises of Ayurveda, “Caraka-Samhitā” (700–100 BC), and the first use of probiotics was mentioned in Ancient China (1000 BC). In the 1670s, Antonie van Leeuwenhoek, using an advanced microscope, described protozoa and bacteria, including intestinal MB. Later, in parallel with the discoveries of Louis Pasteur and Robert Koch, intestinal MB was a subject for research, with studies by Theodor Escherich, Henri Tissier, and our compatriots S.N. Vinogradsky and I.I. Mechnikov playing an important role. The next stage in the study of intestinal MB dates back to 1994 with the beginning of the use of 16s rRNA sequencing, metascience, and the organization of global projects for the MB study, the Human Microbiome Project and METAgenomics of the Human Intestinal Tract, the purpose of which is to study its composition and interaction with the body. An example of such an interaction is the gut-kidney axis, which reflects the metabolic relationship of the kidneys and intestinal MB. Within the context of this axis, the potential therapeutic possibilities of pro-, prebiotics and synbiotics in kidney diseases are investigated. However, despite advances in the field, further research is needed to develop of the most optimal strategy for correcting microbiota disorders, including in chronic kidney diseases.
- 12 July 2025
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 97 (6) , 528-533
Open AccessGut microbiota: Historical essay and role in nephrology
The article covers the main stages of intestinal microbiota (MB) research from ancient to modern times and addresses the features of the interaction between intestinal MB and renal diseases, the gut-kidney axis. It is believed that for the first time, MB was mentioned in one of the treatises of Ayurveda, “Caraka-Samhitā” (700–100 BC), and the first use of probiotics was mentioned in Ancient China (1000 BC). In the 1670s, Antonie van Leeuwenhoek, using an advanced microscope, described protozoa and bacteria, including intestinal MB. Later, in parallel with the discoveries of Louis Pasteur and Robert Koch, intestinal MB was a subject for research, with studies by Theodor Escherich, Henri Tissier, and our compatriots S.N. Vinogradsky and I.I. Mechnikov playing an important role. The next stage in the study of intestinal MB dates back to 1994 with the beginning of the use of 16s rRNA sequencing, metascience, and the organization of global projects for the MB study, the Human Microbiome Project and METAgenomics of the Human Intestinal Tract, the purpose of which is to study its composition and interaction with the body. An example of such an interaction is the gut-kidney axis, which reflects the metabolic relationship of the kidneys and intestinal MB. Within the context of this axis, the potential therapeutic possibilities of pro-, prebiotics and synbiotics in kidney diseases are investigated. However, despite advances in the field, further research is needed to develop of the most optimal strategy for correcting microbiota disorders, including in chronic kidney diseases.
- Open Access
- 8 June 2025
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 97 (5) , 475-480
E.M. Tareev: the importance of scientific heritage for the development of Russian internal medicine (on the 130th anniversary of his birth)
The article is dedicated to the memory of the outstanding Russian internist and scientist, academician of the Russian Academy of Medical Sciences – E.M. Tareev, who had a huge influence on the development of Russian medicine. The life and professional path of the scientist, his most significant scientific achievements in various areas of internal pathology, marked by high state awards and prestigious national prizes, are presented. The basic principles of the scientific school of E.M. Tareev are also presented, including his statements on the importance of maintaining at the present stage a broad general therapeutic approach to solving complex integrated tasks of health care.
- 8 June 2025
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 97 (5) , 475-480
Open AccessE.M. Tareev: the importance of scientific heritage for the development of Russian internal medicine (on the 130th anniversary of his birth)
The article is dedicated to the memory of the outstanding Russian internist and scientist, academician of the Russian Academy of Medical Sciences – E.M. Tareev, who had a huge influence on the development of Russian medicine. The life and professional path of the scientist, his most significant scientific achievements in various areas of internal pathology, marked by high state awards and prestigious national prizes, are presented. The basic principles of the scientific school of E.M. Tareev are also presented, including his statements on the importance of maintaining at the present stage a broad general therapeutic approach to solving complex integrated tasks of health care.
- 17 January 2025
- Published by Non-profit organization Nephrology in Nephrology (Saint-Petersburg)
- Vol. 28 (4) , 45-54
Predictive value of serum Klotho protein level in assessing: cardiovascular risk, achievement of the end stage of CKD, and overall survival of patients with initial CKD C3-4: a prospective clinical analysis (follow-up period of 8 years)
BACKGROUND. Cardiovascular complications (CVС) are the leading cause of death in a cohort of CKD patients, including young working age people. The search for a prognostic marker that allows predicting and preventing the risk of CVС is an important not only medical but also socioeconomic task.THE AIM OF THE STUDY: To determine the predictive value of baseline serum Klotho levels in assessing cardiovascular risk, risk of developing end-stage renal disease (ESRD), and overall survival among patients with stage 3-4 CKD, during an 8-year follow-up period.PATIENTS AND METHODS: The study included 75 patients with CKD C3-4, mean age 54+9 years. The initial serum Klotho level was divided into quartiles (1 quartile Klotho – 148-336 pg/ml; 2-3 quartile – 337-580 pg/ml; 4 quartile – 580-812 pg/ml). The overall survival of patients over a period of 8 years, the cause of death, and the achievement of ESRD, depending on the Klotho quartile, were assessed. RESULTS: During the observation period, 22 patients died, of which 12 (54.5 %) died from CVC, 7 (31.8 %) from covid infection, 3 (13.6 %) from other causes. When assessed by quartiles, patients with the 1st quartile prevailed among the deceased patients, including those from CVC: the 1st quartile was – 9 (75.0 %), the 2nd-3rd quartile -3 (25.0 %), the 4th quartile – 0 ( 0 %), (chi-square = 8.2, p=0.023). Among patients who achieved ESRD and started dialysis (n=30), patients with 1 quartile were 12 (63.2 %), 2-3 quartile -16 (43.2 %), 4 quartile – 2 (10.5 % ), (chi-square = 11.3, p = 0.01). Among the surviving patients (n=53) with CVC on the moment of end study (n=28), patients with 1 quartile were 19 (67.9 %), 2-3 quartile 9 (32.1 %), 4 quartile – 0 % (chisquare=19.9, pCONCLUSION: According to our data, the serum level of Klotho did not depend on the age of patients or the stage of CKD (in the sample of patients with 3-4 stages of CKD), however, it was clearly associated with the risk of cardiovascular events, the risk of progression of CKD to ESRD, overall survival of patients and can be considered as prognostic marker in patients with pre-dialysis stages of CKD.
- 17 January 2025
- Published by Non-profit organization Nephrology in Nephrology (Saint-Petersburg)
- Vol. 28 (4) , 45-54
Predictive value of serum Klotho protein level in assessing: cardiovascular risk, achievement of the end stage of CKD, and overall survival of patients with initial CKD C3-4: a prospective clinical analysis (follow-up period of 8 years)
BACKGROUND. Cardiovascular complications (CVС) are the leading cause of death in a cohort of CKD patients, including young working age people. The search for a prognostic marker that allows predicting and preventing the risk of CVС is an important not only medical but also socioeconomic task.THE AIM OF THE STUDY: To determine the predictive value of baseline serum Klotho levels in assessing cardiovascular risk, risk of developing end-stage renal disease (ESRD), and overall survival among patients with stage 3-4 CKD, during an 8-year follow-up period.PATIENTS AND METHODS: The study included 75 patients with CKD C3-4, mean age 54+9 years. The initial serum Klotho level was divided into quartiles (1 quartile Klotho – 148-336 pg/ml; 2-3 quartile – 337-580 pg/ml; 4 quartile – 580-812 pg/ml). The overall survival of patients over a period of 8 years, the cause of death, and the achievement of ESRD, depending on the Klotho quartile, were assessed. RESULTS: During the observation period, 22 patients died, of which 12 (54.5 %) died from CVC, 7 (31.8 %) from covid infection, 3 (13.6 %) from other causes. When assessed by quartiles, patients with the 1st quartile prevailed among the deceased patients, including those from CVC: the 1st quartile was – 9 (75.0 %), the 2nd-3rd quartile -3 (25.0 %), the 4th quartile – 0 ( 0 %), (chi-square = 8.2, p=0.023). Among patients who achieved ESRD and started dialysis (n=30), patients with 1 quartile were 12 (63.2 %), 2-3 quartile -16 (43.2 %), 4 quartile – 2 (10.5 % ), (chi-square = 11.3, p = 0.01). Among the surviving patients (n=53) with CVC on the moment of end study (n=28), patients with 1 quartile were 19 (67.9 %), 2-3 quartile 9 (32.1 %), 4 quartile – 0 % (chisquare=19.9, pCONCLUSION: According to our data, the serum level of Klotho did not depend on the age of patients or the stage of CKD (in the sample of patients with 3-4 stages of CKD), however, it was clearly associated with the risk of cardiovascular events, the risk of progression of CKD to ESRD, overall survival of patients and can be considered as prognostic marker in patients with pre-dialysis stages of CKD.
- 1 October 2024
- Published by Media Sphere Publishing Group in Russian Journal of Evidence-Based Gastroenterology
- Vol. 13 (3)
Direct-acting antiviral agents for HCV-associated cryoglobulinemic vasculitis. Does viral eradication always lead to the achievement of complete clinical and immunological responses?
Direct-acting antiviral agents (DAAs) are highly effective in treating HCV-associated cryoglobulinemic vasculitis (HCV-CV), achieving a sustained virological response (SVR) in 95—100% of patients. However, some patients still show immunological markers and sporadic vasculitis symptoms post-eradication. Objective. To evaluate clinical and immunological responses in patients with HCV-CV compared to patients with «asymptomatic» HCV-associated cryoglobulinemia (HCV-CG) after a course of DAA therapy during prolonged observation. Material and Methods. The study included 45 patients: 23 with HCV-CV and 22 with HCV-CG, who underwent antiviral therapy with DAAs. Clinical-immunological and virological data were assessed before treatment, at 12 and 48 weeks after treatment. Results. An SVR was achieved in 100% of patients after the DAA course. In patients with HCV-CV, an immunological response was observed in 56.5% by week 12 (SVR12) and 73.9% by week 48 (SVR48). Six patients (26.1%) did not achieve an immunological response by SVR48. The frequency of complete and partial clinical response by SVR12 among these patients was 65.2%, and by SVR48 — 78.3%. In 5 patients (21.7%) manifestations of HCV-CV persisted and/or relapsed. In patients with HCV-CG, the rate of complete and partial immunological response after DAA therapy was 77.3% at SVR12 and 86.3% at SVR48. Three patients showed no response, characterized by trace-level cryoglobulinemia. Conclusion. Most HCV-CV patients reach remission with DAA treatment. However, 20% of patients continue to exhibit/recurrent CV manifestations after treatment. Based on these observations, patients with HCV-CV, especially those with severe initial skin and kidney involvement, require long-term monitoring after achieving SVR.
- 1 October 2024
- Published by Media Sphere Publishing Group in Russian Journal of Evidence-Based Gastroenterology
- Vol. 13 (3)
Direct-acting antiviral agents for HCV-associated cryoglobulinemic vasculitis. Does viral eradication always lead to the achievement of complete clinical and immunological responses?
Direct-acting antiviral agents (DAAs) are highly effective in treating HCV-associated cryoglobulinemic vasculitis (HCV-CV), achieving a sustained virological response (SVR) in 95—100% of patients. However, some patients still show immunological markers and sporadic vasculitis symptoms post-eradication. Objective. To evaluate clinical and immunological responses in patients with HCV-CV compared to patients with «asymptomatic» HCV-associated cryoglobulinemia (HCV-CG) after a course of DAA therapy during prolonged observation. Material and Methods. The study included 45 patients: 23 with HCV-CV and 22 with HCV-CG, who underwent antiviral therapy with DAAs. Clinical-immunological and virological data were assessed before treatment, at 12 and 48 weeks after treatment. Results. An SVR was achieved in 100% of patients after the DAA course. In patients with HCV-CV, an immunological response was observed in 56.5% by week 12 (SVR12) and 73.9% by week 48 (SVR48). Six patients (26.1%) did not achieve an immunological response by SVR48. The frequency of complete and partial clinical response by SVR12 among these patients was 65.2%, and by SVR48 — 78.3%. In 5 patients (21.7%) manifestations of HCV-CV persisted and/or relapsed. In patients with HCV-CG, the rate of complete and partial immunological response after DAA therapy was 77.3% at SVR12 and 86.3% at SVR48. Three patients showed no response, characterized by trace-level cryoglobulinemia. Conclusion. Most HCV-CV patients reach remission with DAA treatment. However, 20% of patients continue to exhibit/recurrent CV manifestations after treatment. Based on these observations, patients with HCV-CV, especially those with severe initial skin and kidney involvement, require long-term monitoring after achieving SVR.
- 2 September 2024
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 38 (1) , 171-179
α-Klotho is associated with cardiovascular and all-cause mortality in patients with stage 3b and 4 chronic kidney disease (CKD): a long-term prospective cohort study
Background α-Klotho deficiency may increase cardiovascular risks and worsen survival. We evaluated the association of α-Klotho with cardiovascular and all-cause mortality in pre-dialysis chronic kidney disease (CKD) patients. Methods In this prospective study, 75 non-diabetic CKD stage 3b–4 patients were followed-up for a median of 8 years. Primary and secondary outcomes were all-cause and cardiovascular mortality, respectively. Human soluble α-Klotho ELISA Assay (IBL-Takara 27,998-96Well), Human Fibroblast Growth Factor-23 ELISA Assay (intact FGF23, Merck Millipore MILLENZ FGF23-32 K), and Human Sclerostin ELISA kits (Biomedica, Vienna, BI-20492) were used to measure serum α-Klotho, FGF23 and sclerostin levels in the certified laboratory at the Sechenov University according to the manufacturers’ protocols. All patients underwent echocardiography to evaluate left ventricular mass index (LVMI), left ventricular ejection fraction by Simpson method, and cardiac (valve) calcification score by a semi-quantitative point scale. Lateral abdominal radiography by Kauppila method was used to estimate calcification of the abdominal aorta. Cox multivariate regression and receiver-operating characteristic curve (ROC)-analysis were used to evaluate risk factors for death and their cut-off values. Results Primary and secondary endpoints were reached in 15 (20%) and 9 (12%) patients, respectively. Median α-Klotho levels in deceased and surviving patients were 344 and 484 pg/ml, respectively (p = 0.002). In a multivariate Cox regression model, baseline α-Klotho levels (HR 0.99, 95% CI 0.98–1.00, p = 0.023), aortic calcification (HR 1.18, 95% CI 1.02–1.36, p = 0.029) and left ventricular mass index (LVMI) (HR 1.04, 95% CI 1.00–1.08, p = 0.033) were associated with the primary endpoint, whereas α-Klotho (HR 0.99, 95% CI 0.98–1.00, p = 0.029), aortic calcification (HR 1.23, 95% CI 1.07–1.42, p = 0.003) and LVMI (HR 1.04, 95% CI 1.00–1.08, p = 0.021) were associated with the secondary endpoint. α-Klotho levels had the highest area under the curve (AUC) by ROC analysis, that is, 0.766 (95% CI 0.70–0.82) for the primary endpoint and 0.842 (95% CI 0.79–0.90) for the secondary endpoint with cut-off values of 412 pg/ml (HR 3.06, 95% CI 1.36–6.89, p = 0.007) and 368 pg/ml (HR 4.84, 95% CI 1.59–14.73, p = 0.005), respectively. Conclusion In pre-dialysis CKD patients, α-Klotho levels are associated with all-cause and cardiovascular mortality and may be considered an early prognostic marker. Graphical abstract
- 2 September 2024
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 38 (1) , 171-179
α-Klotho is associated with cardiovascular and all-cause mortality in patients with stage 3b and 4 chronic kidney disease (CKD): a long-term prospective cohort study
Background α-Klotho deficiency may increase cardiovascular risks and worsen survival. We evaluated the association of α-Klotho with cardiovascular and all-cause mortality in pre-dialysis chronic kidney disease (CKD) patients. Methods In this prospective study, 75 non-diabetic CKD stage 3b–4 patients were followed-up for a median of 8 years. Primary and secondary outcomes were all-cause and cardiovascular mortality, respectively. Human soluble α-Klotho ELISA Assay (IBL-Takara 27,998-96Well), Human Fibroblast Growth Factor-23 ELISA Assay (intact FGF23, Merck Millipore MILLENZ FGF23-32 K), and Human Sclerostin ELISA kits (Biomedica, Vienna, BI-20492) were used to measure serum α-Klotho, FGF23 and sclerostin levels in the certified laboratory at the Sechenov University according to the manufacturers’ protocols. All patients underwent echocardiography to evaluate left ventricular mass index (LVMI), left ventricular ejection fraction by Simpson method, and cardiac (valve) calcification score by a semi-quantitative point scale. Lateral abdominal radiography by Kauppila method was used to estimate calcification of the abdominal aorta. Cox multivariate regression and receiver-operating characteristic curve (ROC)-analysis were used to evaluate risk factors for death and their cut-off values. Results Primary and secondary endpoints were reached in 15 (20%) and 9 (12%) patients, respectively. Median α-Klotho levels in deceased and surviving patients were 344 and 484 pg/ml, respectively (p = 0.002). In a multivariate Cox regression model, baseline α-Klotho levels (HR 0.99, 95% CI 0.98–1.00, p = 0.023), aortic calcification (HR 1.18, 95% CI 1.02–1.36, p = 0.029) and left ventricular mass index (LVMI) (HR 1.04, 95% CI 1.00–1.08, p = 0.033) were associated with the primary endpoint, whereas α-Klotho (HR 0.99, 95% CI 0.98–1.00, p = 0.029), aortic calcification (HR 1.23, 95% CI 1.07–1.42, p = 0.003) and LVMI (HR 1.04, 95% CI 1.00–1.08, p = 0.021) were associated with the secondary endpoint. α-Klotho levels had the highest area under the curve (AUC) by ROC analysis, that is, 0.766 (95% CI 0.70–0.82) for the primary endpoint and 0.842 (95% CI 0.79–0.90) for the secondary endpoint with cut-off values of 412 pg/ml (HR 3.06, 95% CI 1.36–6.89, p = 0.007) and 368 pg/ml (HR 4.84, 95% CI 1.59–14.73, p = 0.005), respectively. Conclusion In pre-dialysis CKD patients, α-Klotho levels are associated with all-cause and cardiovascular mortality and may be considered an early prognostic marker. Graphical abstract
- Open Access
- 7 July 2024
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 96 (6) , 606-613
Anemia of chronic diseases in the early stages of chronic kidney disease as a risk factor for cardiovascular complications in patients with glomerulonephritis
Aim. To determine biomarkers of anemia of chronic disease (ACD) in patients with glomerulonephritis (GN) in the early stages of CKD, to assess their role as risk factors for cardiovascular complications (CVС). Materials and methods. Seventy nine patients with GN were studied, among them: 40 with primary сhronic GN (CGN), 39 with secondary forms:19 – GN with ANCA-associated systemic vasculitis, 20 – GN with systemic lupus erythematosus (SLE) at early (all I–II) CKD stages. In all patients, the level of serum C-reactive protein (CRP), hepcidin, interferon γ, and the circulating form of protein Klotho (s-Klotho) were determined. When a relative iron deficiency was detected [transferrin iron saturation coefficient (TSAT) 20%], patients were administered parenterally iron [III] sucrose hydroxide complex (Venofer). Results. The frequency of anemia among patients with systemic diseases is 3.2 times higher than among patients with primary CGN. Patients with anemia (group I; n=43) had higher rates of daily proteinuria (p0.001), systolic blood pressure (p0.05), serum levels of interferon γ (p0.001) and hepcidin (p0.001) and lower values of eGFR (p0.05) than patients without anemia (group II; n=36). A strong inverse correlation was noted between the level of hepcidin and the content of iron in serum (r=-0.856; p0.001), between the level of hemoglobin and the level of interferon γ (r=-0.447; p0.05), hepcidin (r=-0.459; p0.05) and CRP (r=-0.453; p0.05). A significant inverse correlation was found between the level of hemoglobin and CVC risk factors – the value of systolic blood pressure (r=-0.512; p0.05) and the mass index of the left ventricular myocardium (r=-0.619; p0.01). At the same time, the contribution of 2 from 6 analyzed factors, hepcidin and eGFR, to the development of ACD was 92.5%, of which 86.6% accounted for hepcidin. A strong direct correlation was also found between a decrease in hemoglobin level and a decrease in the level of s-Klotho protein (r=0.645; p0.001), a decrease in the level of s-Klotho and an increase in the level of serum hepcidin (r=-0.541; p0.05). The leading value of anemia (beta -0,29; p=0,04) and depression of the s-Klotho level (beta -0,44; p=0,02) as independent cardiovascular risk factors in this group of patients was confirmed by multivariate analysis. In patients with identified deficiency of iron (n=40), after 3–4 weeks of intravenous administration of venofer, the target level of hemoglobin (Нb120 g/l) and transferrin saturation with iron (TSAT20%) were achieved. Conclusion. Among the biomarkers of ACD in patients with immunoinflammatory diseases of the kidneys (primary and secondary СGN), the increase in the serum level of hepcidin is greatest importance. The concomitant to anemia decrease in s-Klotho is a leading risk factor for CVС in CKD. Early correction of ACD with iron supplements makes it possible to achieve target levels of Hb and TSAT and have subsequently a positive effect on the production of s-Klotho and the severity of left ventricular hypertrophia.
- 7 July 2024
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 96 (6) , 606-613
Open AccessAnemia of chronic diseases in the early stages of chronic kidney disease as a risk factor for cardiovascular complications in patients with glomerulonephritis
Aim. To determine biomarkers of anemia of chronic disease (ACD) in patients with glomerulonephritis (GN) in the early stages of CKD, to assess their role as risk factors for cardiovascular complications (CVС). Materials and methods. Seventy nine patients with GN were studied, among them: 40 with primary сhronic GN (CGN), 39 with secondary forms:19 – GN with ANCA-associated systemic vasculitis, 20 – GN with systemic lupus erythematosus (SLE) at early (all I–II) CKD stages. In all patients, the level of serum C-reactive protein (CRP), hepcidin, interferon γ, and the circulating form of protein Klotho (s-Klotho) were determined. When a relative iron deficiency was detected [transferrin iron saturation coefficient (TSAT) 20%], patients were administered parenterally iron [III] sucrose hydroxide complex (Venofer). Results. The frequency of anemia among patients with systemic diseases is 3.2 times higher than among patients with primary CGN. Patients with anemia (group I; n=43) had higher rates of daily proteinuria (p0.001), systolic blood pressure (p0.05), serum levels of interferon γ (p0.001) and hepcidin (p0.001) and lower values of eGFR (p0.05) than patients without anemia (group II; n=36). A strong inverse correlation was noted between the level of hepcidin and the content of iron in serum (r=-0.856; p0.001), between the level of hemoglobin and the level of interferon γ (r=-0.447; p0.05), hepcidin (r=-0.459; p0.05) and CRP (r=-0.453; p0.05). A significant inverse correlation was found between the level of hemoglobin and CVC risk factors – the value of systolic blood pressure (r=-0.512; p0.05) and the mass index of the left ventricular myocardium (r=-0.619; p0.01). At the same time, the contribution of 2 from 6 analyzed factors, hepcidin and eGFR, to the development of ACD was 92.5%, of which 86.6% accounted for hepcidin. A strong direct correlation was also found between a decrease in hemoglobin level and a decrease in the level of s-Klotho protein (r=0.645; p0.001), a decrease in the level of s-Klotho and an increase in the level of serum hepcidin (r=-0.541; p0.05). The leading value of anemia (beta -0,29; p=0,04) and depression of the s-Klotho level (beta -0,44; p=0,02) as independent cardiovascular risk factors in this group of patients was confirmed by multivariate analysis. In patients with identified deficiency of iron (n=40), after 3–4 weeks of intravenous administration of venofer, the target level of hemoglobin (Нb120 g/l) and transferrin saturation with iron (TSAT20%) were achieved. Conclusion. Among the biomarkers of ACD in patients with immunoinflammatory diseases of the kidneys (primary and secondary СGN), the increase in the serum level of hepcidin is greatest importance. The concomitant to anemia decrease in s-Klotho is a leading risk factor for CVС in CKD. Early correction of ACD with iron supplements makes it possible to achieve target levels of Hb and TSAT and have subsequently a positive effect on the production of s-Klotho and the severity of left ventricular hypertrophia.
- 12 September 2023
- Published by Non-profit organization Nephrology in Nephrology (Saint-Petersburg)
- Vol. 27 (3) , 44-52
Therapy with direct antiviral drugs in patients with HCVassociated cryoglobulinemic vasculitis – is it always possible to achieve complete clinical and immunological responses after the virus eradication?
Background. The use of direct acting antiviral drugs (DAАs) leads to the achievement of a stable virological response (SVR) in 95–100 % of patients with HCV-associated cryoglobulinemic vasculitis (HCV-CV). However, in some patients, despite the eradication of the virus, clinical and immunological markers of vasculitis still remain.The aim: to evaluate clinical and immunological responses in patients with HCV-CV in comparison with patients with "asymptomatic" HCV- associated cryoglobulinemia (HCV- СG) after achieving SVR with the help of DAАs with long-term dynamic observation (12 months).Patients and Methods: The study included 45 patients: 23 with HCV-CV and 22 with "asymptomatic" HCV-CG, who underwent antiviral therapy with DAAs. Clinical-immunological, virological data were evaluated: before treatment, 12 weeks (3 months) and 48 weeks (12 months) after the end of treatment.Results: After a course of DAAs, SVR was diagnosed in all 45 (100 % of patients). In patients with HCV-CV, an immunological response (complete and partial) was observed by week 12 (SVR12) – in 56.5 % and by week 48 (SVR48) – in 73.9 % patients. In 6 patients (26.1 %), the immunological response was not achieved by SVR48. The rate of complete and partial clinical response 12 weeks after the end of treatment at the SVR12 period in patients with HCV-CV was 65.2 %, to the time of SVR48 amounted to 78.3 % patients. In 5 (21.7 %) individual manifestations of CV persisted and/or relapsed. In patients with HCV-CG, the frequency of complete and partial immunological responses after DAAs therapy was 77.3 % – by SVR12 and 86.3 % – by SVR48, respectively. No response was observed in 3 patients and it was characterized by trace-level of cryoglobulinemia.Conclusion: In most patients with HCV-CV eradication of HCV with help of DAAs leads to the achievement of clinical and immunological remission of the disease. However, in 20 % of patients manifestations of HCV-CV persist / recur immediately after the end of treatment or later relapses are observed. Based on these observations, patients with HCV-CV, especially those with severe underlying skin and kidney disease, are required long-term monitoring after SVR is achieved.
- 12 September 2023
- Published by Non-profit organization Nephrology in Nephrology (Saint-Petersburg)
- Vol. 27 (3) , 44-52
Therapy with direct antiviral drugs in patients with HCVassociated cryoglobulinemic vasculitis – is it always possible to achieve complete clinical and immunological responses after the virus eradication?
Background. The use of direct acting antiviral drugs (DAАs) leads to the achievement of a stable virological response (SVR) in 95–100 % of patients with HCV-associated cryoglobulinemic vasculitis (HCV-CV). However, in some patients, despite the eradication of the virus, clinical and immunological markers of vasculitis still remain.The aim: to evaluate clinical and immunological responses in patients with HCV-CV in comparison with patients with "asymptomatic" HCV- associated cryoglobulinemia (HCV- СG) after achieving SVR with the help of DAАs with long-term dynamic observation (12 months).Patients and Methods: The study included 45 patients: 23 with HCV-CV and 22 with "asymptomatic" HCV-CG, who underwent antiviral therapy with DAAs. Clinical-immunological, virological data were evaluated: before treatment, 12 weeks (3 months) and 48 weeks (12 months) after the end of treatment.Results: After a course of DAAs, SVR was diagnosed in all 45 (100 % of patients). In patients with HCV-CV, an immunological response (complete and partial) was observed by week 12 (SVR12) – in 56.5 % and by week 48 (SVR48) – in 73.9 % patients. In 6 patients (26.1 %), the immunological response was not achieved by SVR48. The rate of complete and partial clinical response 12 weeks after the end of treatment at the SVR12 period in patients with HCV-CV was 65.2 %, to the time of SVR48 amounted to 78.3 % patients. In 5 (21.7 %) individual manifestations of CV persisted and/or relapsed. In patients with HCV-CG, the frequency of complete and partial immunological responses after DAAs therapy was 77.3 % – by SVR12 and 86.3 % – by SVR48, respectively. No response was observed in 3 patients and it was characterized by trace-level of cryoglobulinemia.Conclusion: In most patients with HCV-CV eradication of HCV with help of DAAs leads to the achievement of clinical and immunological remission of the disease. However, in 20 % of patients manifestations of HCV-CV persist / recur immediately after the end of treatment or later relapses are observed. Based on these observations, patients with HCV-CV, especially those with severe underlying skin and kidney disease, are required long-term monitoring after SVR is achieved.
- Open Access
- 17 August 2023
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 95 (6) , 521-525
Cardiorenal syndromes: historical aspects and current challenges
The article describes major milestones in acknowledgment of pathophysiological relationship between heart and kidneys since Ancient Egypt till our time and history of term cardiorenal syndrome (CRS). First references about kidney and heart functions could be dated to 13 BC when Hippocrates mentioned them. In the XIV century Gentile da Foligno proposed a hypothesis about functional interconnection between heart and kidneys. In the XVIII century Richard Bright described the link between myocardial hypertrophy and kidneys diseases. Frederic Justin Collet was the first one who used the term cardiorenal in his article in 1903. In Russia, I.I. Stolnikov conducted his experiments about myocardial hypertrophy and kidneys ischemia in 1880. Famous Russian internist, E.M. Tareev, devoted several paragraphs to cardiorenal interactions in his fundamental manuals Anemia in Brights disease (1929) and Hypertension (1948). The research on this topic was continued by Tareevs followers: N.A. Mukhin, V.S. Moiseev, more recent successors Zh.D. Kobalava, S.V. Moiseev, V.V. Fomin, S.V. Villevalde and others. Their contribution resulted in development of first Russian clinical guidelines on cardio and nephroprotection in CRS in 2014. In 2008 consensus of Acute Disease Quality Initiative summarized current experience on CRS. Today, research on controversial classification questions, biomarkers and other aspects of CRS continues.
- 17 August 2023
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 95 (6) , 521-525
Open AccessCardiorenal syndromes: historical aspects and current challenges
The article describes major milestones in acknowledgment of pathophysiological relationship between heart and kidneys since Ancient Egypt till our time and history of term cardiorenal syndrome (CRS). First references about kidney and heart functions could be dated to 13 BC when Hippocrates mentioned them. In the XIV century Gentile da Foligno proposed a hypothesis about functional interconnection between heart and kidneys. In the XVIII century Richard Bright described the link between myocardial hypertrophy and kidneys diseases. Frederic Justin Collet was the first one who used the term cardiorenal in his article in 1903. In Russia, I.I. Stolnikov conducted his experiments about myocardial hypertrophy and kidneys ischemia in 1880. Famous Russian internist, E.M. Tareev, devoted several paragraphs to cardiorenal interactions in his fundamental manuals Anemia in Brights disease (1929) and Hypertension (1948). The research on this topic was continued by Tareevs followers: N.A. Mukhin, V.S. Moiseev, more recent successors Zh.D. Kobalava, S.V. Moiseev, V.V. Fomin, S.V. Villevalde and others. Their contribution resulted in development of first Russian clinical guidelines on cardio and nephroprotection in CRS in 2014. In 2008 consensus of Acute Disease Quality Initiative summarized current experience on CRS. Today, research on controversial classification questions, biomarkers and other aspects of CRS continues.